<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16453">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01675609</url>
  </required_header>
  <id_info>
    <org_study_id>11-100-0015</org_study_id>
    <nct_id>NCT01675609</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Safety and Efficacy of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects</brief_title>
  <official_title>A Single-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eye Therapies, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eye Therapies, LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of brimonidine tartrate
      0.025% ophthalmic solution used four times daily in a population of adult and geriatric
      subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Ocular redness</measure>
    <time_frame>at specified timepoints for up to 180 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>redness evaluated by investigator prior to study medication instillation and redness evaluated by the subject as captured in dosing diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular Redness</measure>
    <time_frame>up to 5 minutes post study medication instillation</time_frame>
    <safety_issue>No</safety_issue>
    <description>evaluated prior to study medication instillation and at 5 minutes post instillation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Ocular Redness</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Brimonidine Tartrate 0.025%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 drop in each eye daily for up to 35 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine tartrate 0.025%</intervention_name>
    <description>1 drop in each eye for up to 35 days</description>
    <arm_group_label>Brimonidine Tartrate 0.025%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be at least 40 years of age

          -  Must have normal ocular health

          -  Must have history of redness relief drop use or desire to use

        Exclusion Criteria:

          -  Must not have any ocular/systemic health problems

          -  Must agree to avoid disallowed medications
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ora, Inc.</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 24, 2013</lastchanged_date>
  <firstreceived_date>August 28, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brimonidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
